The medical oncologist at the Mayo Clinic in Phoenix, spoke about the progress seen in gastrointestinal cancer research in 2020, as well as what improvements he hopes will occur in 2021.
Though this year brought many challenges, including navigating the coronavirus disease 2019 (COVID-19) pandemic, advancements in gastrointestinal cancer research still persisted.
In April, during the height of the COVID-19 pandemic, the FDA approved pemigatinib (Pemazyre) for advanced cholangiocarcinoma – a first for this patient population. Just a month later, the FDA also approved atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy. Moreover, the FDA is still reviewing a slew of agents for the treatment of gastrointestinal cancer.
In an interview with CancerNetwork®, Tanios Bekaii-Saab,MD, a medical oncologist at the Mayo Clinic in Phoenix, Arizona, discussed the advancements made in gastrointestinal cancer in 2020, as well as what improvements he hopes will occur in 2021.
This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
FDA Updates Indication for Pembrolizumab in HER2+ Gastric/GEJ Adenocarcinoma
November 9th 2023Only patients with PD-L1–positive tumors may receive treatment with pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma following the FDA’s amendment.
Domvanalimab Plus Zimberelimab Improve Efficacy in Gastrointestinal Cancers
November 7th 2023Results from arm A1 of the phase 2 EDGE-Gastric study indicate that patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma experienced improved responses after receiving domvanalimab/zimberelimab.